遠翔新材(301300.SZ):產品暫未涉及半導體封裝材料和CPO封裝領域
格隆匯7月23日丨遠翔新材(301300.SZ)在互動平臺表示,公司主營業務聚焦納米二氧化硅的研發、生產和銷售。現有產品主要作爲原材料應用於硅橡膠領域,終端應用場景覆蓋電子、電線電纜、汽車、醫療等傳統行業,並持續拓展至智能穿戴設備(運動手環/健康監測產品)、食品級母嬰用品(硅膠玩具/嬰兒護理品)、仿生皮膚、皮革、柔性電子屏配套材料等新興消費領域。另外公司在持續鞏固硅橡膠用二氧化硅市場的同時積極向牙膏、PE蓄電池隔板、塗料消光劑、消泡劑以及絕熱材料等應用領域拓展。目前公司產品暫未涉及半導體封裝材料和CPO封裝領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.